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Abstract: Annual wormwood (AW) (Artemisia annua L.) has anti-malarial, anti-bacterial, anti-oxidant,
anti-tumour, and anti-inflammatory activities. In the present study, we evaluated the effects of
annual wormwood leaves (AWL) on adipocyte differentiation in 3T3-L1 cells and high-fat diet
(HFD)-induced obese rats. 3T3-L1 adipocytes and HFD-induced obese rats were treated with AWL,
and its effect on gene expression was analyzed using RT-PCR and Western blotting experiments.
Treatment with AWL effectively prevented triglyceride accumulation during adipogenesis in
a dose-dependent manner. Consistently, AWL suppressed the differentiation of 3T3-L1 preadipocytes
into adipocytes through the downregulation of dexamethasone, 3-isobutyl-1- methylxanthine, and
insulin (DMI)-induced serine/threonine kinase protein kinase B (PKB/Akt) activation and the
expression of adipogenic genes, including the CCAAT/enhancer binding protein-α (C/EBPα) and
peroximal proliferator-activated receptor-γ (PPARγ). Moreover, the expression of adipocyte fatty
acid-binding protein 4 (aP2), which is a known PPARγ-target gene, was downregulated by AWL
treatment. Oral administration of AWL extracts significantly decreased the body weight gain,
adipose tissue mass, adipocyte cell size, serum triglyceride (TG), and total cholesterol (TC) levels
in HFD-induced obese rats. These results provide novel insight into the molecular mechanisms
underlying the anti-obesity effects of AWL that are mediated by the downregulation of the expression
of major adipogenic transcription factors, C/EBPα and PPARγ and Akt signalling.
Keywords: annual wormwood leaf; 3T3-L1 cells; adipogenesis; high-fat diet; PPARγ; Akt
1. Introduction
Obesity is a condition in which a person has an abnormally high and unhealthy proportion
of body fat. Obesity is a major risk factor for many metabolic disorders, including hyperlipidemia,
diabetes mellitus, atherosclerosis, hypertension, and cardiovascular disease [1]. Physiologically, obesity
is associated with increased levels of adipocytes and an increase in adipocyte volume. Although
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accumulated intracellular triglycerides can be broken down by exercise or diet, obesity caused by
increased fat-cell size and the number is difficult to treat, as the fat cells must be destroyed or removed.
Adipogenesis is a multi-step process involving a cascade of transcription factors and
adipocyte-specific gene expression leading to adipocyte development. Lipid accumulation reflects
the process of adipogenesis, which is regulated by genetic and growth factors [2,3]. Adipogenesis
is a differentiation process by which preadipocyte cells undergo terminal differentiation to mature
adipocytes. CCAAT/enhancer binding protein-δ (C/EBPδ) and CCAAT/enhancer binding protein-β
(C/EBPβ) are rapidly and transiently expressed after the hormonal induction of differentiation [4,5].
These genes act synergistically to promote the expression of CCAAT/enhancer binding protein-α
(C/EPBα) and peroximal proliferator-activated receptor-γ (PPARγ), which are the master adipogenic
transcription factors [6,7]. After differentiation, adipocytes regulate lipid metabolism through lipogenic
proteins such as fatty acid synthase (FAS) and aP2 [7].
Insulin and Akt signalling modulates adipose tissue growth and adipogenesis [8]. Insulin
stimulates glucose and free fatty acid uptake, inhibits lipolysis, and stimulates de novo fatty acid
synthesis in adipocytes. The Ser/Thr kinase Akt plays an essential role in adipocyte differentiation.
Mouse embryonic fibroblasts (MEFs) lacking Akt display an inability to differentiate into adipocytes [9],
and an RNAi-mediated decrease in Akt was found to block the differentiation of 3T3-L1 cells [10].
Glycogen synthase kinase-3β (GSK-3β), which controls glycogen and protein synthesis among many
other cellular processes, was one of the first described physiological targets of Akt [11].
Recently, the medical use of natural plant products could provide more effective and less expensive
medications for people than ever before. Artemisia annua L., also known as annual wormwood
(AW), is a common type of wormwood that belongs to the family Asteraceae. Annual wormwood
leaves (AWL) have been used for many centuries in traditional medicine in Asia in the treatment
of febrile diseases and malaria. Among major components such as monoterpenes, camphor, and
Artemisia ketone in Artemisia annua L., artemisinin, which has a critical role in anti-oxidant and
anti-inflammatory with formula C15H22O15 and characterized by structural features, contains a
peroxide bridge (C-O-O-C) [12]. As an important biological functional, artemisinin is known to
have anti-bacterial, anti-fungal, anti-leishmanial, anti-oxidant, anti-tumour, and anti-inflammatory
activities [13–15]. In particular, artemisinic acid isolated from AW inhibited adipogenic differentiation
of human adipose tissue-derived mesenchymal stem cells [16].
Annual wormwood is associated with many health benefits. However, it remains unknown how
AWL promotes an anti-obesity effect in 3T3-L1 adipocytes and high fat diet (HFD)-induced obese
rats. In the present study, the effect of AWL extracts on adipocyte differentiation in 3T3-L1 cells
were investigated by measuring the accumulation of intracellular droplets of triglyceride as well as
the expression levels of several adipogenesis-related genes. Moreover, in order to understand the
specific mechanisms of these effects, we examined whether Akt and GSK3β activation is critical for the
anti-adipogenic functions of AWL. We further evaluate anti-obesity effects of AWL in obese rats fed
high-fat diets (HFDs).
2. Materials and Methods
2.1. Preparation of Annual Wormwood Leaf (AWL) Extracts
Fresh leaves of annual wormwood (AW) were collected immediately after harvesting in May 2016
at Jinju, Gyeongnam (Animal Bio-Resources Bank, Gyeongnam, Korea). Annual wormwood leaves
(AWL) were authenticated by Professor T. H. Kim in the Department of Food Science and Biotechnology,
Daegu University, Korea. Fresh samples of annual wormwood leaves were prepared by alcohol
extraction. The leaves were chopped after washing with running water, dried in oven at 40 ◦C for
2 days followed by grinding to a powder. The AWL (30 g) powder was then suspended in an 80%
(v/v) ethanol solution using a mixer, followed by extraction of the samples for 3 days with vigorous
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shaking at room temperature and filtering through Whatman No. 1 filter paper. The ethanolic extracts
of AWL were concentrated using rotary-vacuum evaporation at 50 ◦C and then freeze-dried.
2.2. Cell Culture
Mouse 3T3-L1 preadipocytes were purchased from the Korean Cell Line Bank (Seoul, Korea)
and cultured as described elsewhere [17]. In brief, cells were cultured in Dulbecco’s Modified
Eagle High-glucose Medium (DMEM) supplemented with 10% calf serum at 37 ◦C in a humidified
atmosphere of 5% CO2. At 1 day postconfluence (designated “day 0”), cell differentiation was
induced with a mixture (DMI) of 0.5 mM 3-isobutyl-1-methylxanthine, 100 µM indomethacin, 0.25 µM
dexamethasone and 167 nM insulin in DMEM containing 10% FBS. The 3-isobutyl-1-methylxanthine
(MIX), dexamethasone (DEX), indomethacin, and Oil Red O were obtained from Sigma-Aldrich
(St. Louis, MO, USA). The medium was changed every 2 days. AWLs were added to the culture medium
of the adipocytes on day 0. The cells were treated with 0, 25, or 100 µg/mL of AW extracts every day.
After treatment with AWL for 4 and 7 days, the 3T3-L1 adipocytes were lysed for Western blot analysis.
To analyse cell viability, the cytotoxicity of the AWL was evaluated using 3-(4, 5-demethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT).
2.3. Oil Red O Staining
The cellular lipid content was assessed by Oil Red O staining (Sigma, St. Louis, MO, USA).
Cells were treated either with AWL extracts (25 µg/mL or 100 µg/mL) or vehicles in the differentiation
medium for days 0–7 of adipogenesis. On days 4 or 7, cells were stained with Oil Red O. For Oil Red O
staining, cells were washed gently with phosphate-buffered saline (PBS), and stained with filtered Oil
Red O solution (60% isopropanol and 40% water) for 30 min. After staining the lipid droplets red, the Oil
Red O staining solution was removed and the plates were rinsed with water and dried. After 3 washes
with PBS, cells were photographed with a 12-megapixel digital camera (Canon, Tokyo, Japan).
2.4. Measurement of Triglyceride Content
Cellular triglyceride content was measured using a commercial Triglyceride Assay Kit
(Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer’s instructions. Adipocytes
differentiated for 4 or 7 days were treated with the AWL at concentrations of 0, 25 and 100 µg/mL in
6-well plates. To analyse the content of cellular triglycerides, cells were washed with PBS and then
scraped into 200 µL PBS and homogenized by sonication for 1 min. The lysates were assayed for total
triglycerides using the assay kits.
2.5. RT-PCR
RNA was isolated from 3T3-L1 adipocytes or epididymal adipocyte tissue using the RNeasy plus
Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. Two micrograms
of total RNA was used for first-strand cDNA synthesis with oligo (deoxythymidine) primers
and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The target cDNA was
amplified using the following primers: C/EBPβ, 5′-GACTACGCAACACACGTGTAACT-3′ and
5′-CAAAACCAAAAACATCAACAACCC-3′; PPARγ, 5′-TTTTCAAGGGTGCCAGTTTC-3′ and
5′-AATCCTTGGCCCTCTGAGAT-3′; C/EBPα, 5′-TTACAACAGGCCAGGTTTCC-3′ and 5′-GGCTG
GCGACATACAGATCA-3′; aP2, 5′-TGATGCCTTTGTGGGAACCT-3′ and 5′-GCAAAGCCCAC
TCCCACTT-3′; ACC, 5′-GAATCTCCTGGTGACAATGCTTATT-3′ and 5′-GGTCTTGCTGAGTTG
GGTTAGC-3′; FAS, 5′-TGTGAGTGGTTCAGAGGCAT-3′ and 5′-TTCTGTAGTGCCAGCAAGCR-3′;
β-actin (control), 5′-GACAACGGCTCCGGCATGTGCAAAG-3′ and 5′-TTCACGGTTGGC
CTTAGGGTTCAG-3′. The amplification cycles included denaturation at 95 ◦C for 50 s, annealing at
55 ◦C for 1 min and elongation at 72 ◦C for 50 s. After 30 cycles, the PCR products were separated by
electrophoresis on a 1.5% agarose gel for 30 min at 100 V. The gene mRNA levels were normalized
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using β-actin. The gels were stained with 1 mg/mL ethidium bromide and visualized with UV light
using Bio-Rad Gel Doc image analysis software (Bio-Rad Laboratories Inc., Hercules, CA, USA).
2.6. Western Blot Analysis
Western blotting was performed according to standard procedures. Briefly, cells were lysed
in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 0.4% Nonidet P-40, 120 mM NaCl, 1.5 mM
MgCl2, 0.1% sodium dodecyl sulfate (SDS), 2 mM phenylmethylsulfonyl fluoride, 80 µg/mL leupeptin,
3 mM NaF and 1 mM Dithiothreitol (DTT). Cell lysates (50 µg protein) were separated by 10%
SDS-polyacrylamide gel electrophoresis, transferred onto a polyvinylidene fluoride membrane
(Amersham Pharmacia, Little Chalfont, England, UK), blocked with 5% skim milk and hybridized
with primary antibodies. PPARγ, C/EBPβ, C/EBPα, aP2, Akt, and GSK3β antibody were from Cell
Signaling (Danvers, MA, USA) and the monoclonal β-actin antibody was from Chemicon (Temecula,
California, USA). Horseradish peroxidase (HRP)-labelled mouse anti-rabbit IgG were from Jackson
ImmunoResearch (West Grove, PA, USA). The Chemiluminescence Kit was from Pierce (Rockford,
IL, USA). After incubation with horseradish-peroxidase-conjugated secondary antibody at room
temperature, immunoreactive proteins were detected using a chemiluminescent ECL Assay Kit
(Amersham Pharmacia, Little Chalfont, England, UK) according to the manufacturer’s instructions.
2.7. Animals and Diets
Four-week-old Sprague–Dawley male rats were purchased from Central Lab Animal Inc. (Seoul,
Korea). All animal experiments were performed following the ethical guidelines set out by the
Gyeongsang National University’s institutional animal care and with the approval of the Animal Care
and Use committee of Gyeongsang National University (Approval Number: GNU-160912-R0032).
The experiments began after acclimating the animals for 7 days under constant conditions of
temperature (22 ◦C), humidity (55%), and light (12 h cycle dark/light) in polycarbonate cages.
The animals were randomly divided into three groups (n = 10) and fed the normal or experimental
diets for 5 weeks as follows: (1) a normal diet group (ND, n = 10); (2) a high-fat diet group (HFD,
n = 10); (3) a AWL group (HFD + AWL 150 mg/kg BW, n = 10). Rats in the ND group were fed a
normal diet (#55VXT0038, Samyang Co., Seoul, Korea). Feeding rats a high-fat diet produced obese
rats, and rats in the HFD groups were fed an HFD based on a commercial diet (rodent diet with 60%
kcal fat, Research Diet, Seoul, Korea). The animals were allowed free access to food and water for five
weeks. Food intake was measured daily, and the rats were weighed twice per week. At the end of the
experiment period, rats were sacrificed after 12 h of fasting.
2.8. Biochemical Analysis
Whole blood samples were centrifuged in a tube containing heparin as anti-coagulant, and
isolated serum was used for analysis of triglyceride (TG), total-cholesterol (TC), and high-density
lipoprotein-cholesterol (HDL-C). After centrifugation, the organic layer was removed and dried.
The resulting pellet was dissolved in phosphate-buffered saline containing 1% Triton X-100,
and the triglyceride content was determined using a commercially available Enzymatic Reagent
Kit (Asan phams, Co., Hwaseon-si, Korea). The concentrations of total-cholesterol (TC) and
high-density lipoprotein-cholesterol (HDL-C) were assayed enzymatically using the commercial
kits (Asan phams, Co., Korea).
2.9. Histological Analysis
Epididymal fat tissues were removed and fixed in 10% neutral-buffered formalin. The fat pads
were subsequently embedded in paraffin, sectioned into 5 µm sections (Leica, Wetzlar, Germany), and
stained with haematoxylin-eosin for microscopic assessment (Olympus, Tokyo, Japan). Three different
cross-sectional areas and their corresponding cell populations were assessed using an image analysis
program (Image-Pro Plus Version 6.0, Rockville, MD, USA).
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2.10. Statistical Analysis
Each experiment was performed at least three times. The data are expressed as the mean ± SD.
One-way ANOVA and the Duncan’s multiple tests were used to determine the significant differences
between the treatment groups. A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Inhibition of Lipid Accumulation by AWL in 3T3-L1 Adipocytes
Two-days post confluence, 3T3-L1 cells were treated with indicated concentrations of AWL and
then stimulated with DMI mixture for 7 days. 3T3-L1 cells were stained with the triglyceride-specific Oil
Red O 4 or 7 days after the induction of adipocyte differentiation. The quantitation of Oil Red O staining
indicated that treatment with the 25 and 100 µg/mL concentration of AWL markedly attenuated
adipocyte differentiation, and treatment with AWL (25, 100 µg/mL) induced a dose-dependent
decrease in lipid levels, as assessed by an strong decrease in 100 µg/mL AWL-treated cells (Figure 1A).
In particular, by day 7, differentiated 3T3-L1 cells revealed a 4–5-fold greater constitutive level of
triglyceride content when compared to undifferentiated cells. However, intracellular triglyceride
accumulation was decreased by 43% in the 100 µg/mL AWL treated 3T3-L1 adipocyte compared
with fully differentiated adipocytes (Figure 1B). A cell viability assay was performed to examine
the possibility that the AWL effect was simply a consequence of cytotoxicity. At a concentration of
100 µg/mL, AWL had no significant activity on cell viability compared to controls and did not cause
cytotoxicity in the 3T3-L1 cells after 4 or 7 days of incubation (Figure 1C). Together, these results
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Figure 1. Effects of AWL on  lipid accumulation and adipocyte differentiation  in 3T3‐L1 cells.  (A). 
3T3‐L1 cells were  induced  to differentiate with DMI and AWL  in  increasing concentrations  (0, 25, 
and 100 μg/mL) for seven days. The cellular lipid content was assessed by Oil Red O staining. DMI: 
0.5 mM 3‐IBMX, 100 μM indomethacin, 0.25 μM dexamethasone and 167 nM insulin. AWL: annual 
wormwood  leaves  extracts.  (B)  AWL  inhibited  TG  accumulation  in  3T3‐L1  adipocytes.  Three 
independent experiments were used to represent the error bars. * p < 0.05, ** p < 0.01. (C) cytotoxicity 
of AWL in 3T3‐L1 cells. Viability of the AWL‐treated cells was determined by the MTT assay. The 
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However, after  treatment with AWL  (25 or 100 mg/mL)  for  four or seven days, C/EBPβ, C/EBPα, 
PPARγ, and aP2  level were significantly decreased during differentiation  to adipocytes  in 3T3‐L1 
cells  (Figure 2A,B). Next,  to examine  the protein expression patterns of adipogenic‐specific genes 
during  3T3‐L1 differentiation, protein  levels of C/EBPβ, C/EBPα,  and PPARγ were measured by 
Figure 1. Effects of AWL on lipid accumulation and adipocyte differentiation in 3T3-L1 cells. (A). 3T3-L1
cells were induced to differentiate with DMI and AWL in increasing concentrations (0, 25, and
100 µg/mL) for seven days. The cellular lipid content was assessed by Oil Red O staining. DMI: 0.5 mM
3-IBMX, 100 µM indomethacin, 0.25 µM dexamethasone and 167 nM insulin. AWL: annual wormwood
leaves extracts. (B) AWL inhibited TG accumulation in 3T3-L1 adipocytes. Three independent
experiments were used to represent the error bars. * p < 0.05, ** p < 0.01. (C) cytotoxicity
of AWL in 3T3-L1 cells. Viability of the AWL-treated cells was determined by the MTT assay.
The values are presented as the means ± SD. The data shown are representative of at least three
independent experiments.
3.2. Effects of L on the R and Protein Levels of enes Involved in dipogenesis and Lipogenesis in
3T3-L1 Cells
To examine the effect of AWL on adipogenic genes, we investigated the expression levels of
C/EBPβ, C/EBPα, PPARγ, and aP2 in 3T3-L1 cells cultured in the presence or absence of AWL (25 or
100 µg/mL) with adipocyte differentiation for four or seven days. We found that the expression
levels of C/EBPβ, C/EBPα, PPARγ, and aP2 mRNA increased in differentiated 3T3-L1 adipocytes.
However, after treatment with AWL (25 or 100 mg/mL) for four or seven days, C/EBPβ, C/EBPα,
PPARγ, and aP2 level were significantly decreased during differentiation to adipocytes in 3T3-L1 cells
(Figure 2A,B). Next, to examine the protein expression patterns of adipogenic-specific genes during
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3T3-L1 differentiation, protein levels of C/EBPβ, C/EBPα, and PPARγ were measured by Western
blot analysis. The expression levels of C/EBPβ, C/EBPα, and PPARγ were dose-dependently reduced
after AWL treatment for four or seven days (Figure 2C). These results indicated that AWL blocked
3T3-L1 adipocyte differentiation via the downregulation of C/EBPβ, C/EBPα, and PPARγ expression.
Moreover, to determine whether the repression of PPARγ and C/EBPα cause the downregulation
of their target gene, aP2, we examined the activation of aP2 under the same conditions. Treatment
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Figure 2. Effects of AWL on adipogenic factors in 3T3-L1 adipocytes. (A) AWL decreased the expression
of adipogenic factors in 3T3-L1 adipocytes at day 4 by RT-PCR. Similar results were obtained by three
independent experiments; (B) AWL inhibited the expression of adipogenic factors in 3T3-L1 adipocytes
at day 7 by RT-PCR. The figure is representative of three independent experiments with identical results.
Optical density analysis was performed to quantify the levels of mRNA expression with β-actin as
loading control. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared with DMI group. (C) AWL inhibited
the expression of genes related to adipogenesis and lipogenesis in 3T3-L1 adipocytes at days 4 and 7 as
determined by a Western blot assay.
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3.3. Effect of AWL on Akt and GSK3β Phosphorylation during Adipocyte Differentiation
The Akt pathway has an important role in controlling adipogenesis. In the present study, we
determined whether Akt phosphorylation was involved in AWL-induced adipocyte differentiation
blockage. 3T3-L1 cells were induced to differentiate with various concentrations of AWL (0, 25, and
100 µg/mL) in the presence of DMI or DMI mixture alone. We investigated the protein expression
of Akt, GSK3β and their phosphorylation forms. In control cells, DMI-stimulated 3T3-L1 adipocytes
showed a significant increase in phospho-Akt (Ser473) and phospho-GSK3β (Ser9) (Figure 3A,B).
In contrast, AWL treatment strongly inhibited the phosphorylation levels of Akt and GSK3β, while
AWL had no inhibitory effect of total Akt and GSK3β expression (Figure 3A,B). These results
suggest that AWL inhibited the phosphorylation of Akt, which was associated with the suppressed
phosphorylation of its substrate kinase GSK3β.
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Figure 3. Effects of AWL treatment on insulin-stimulated Akt and GSK3β phosphorylation in 3T3-L1
adipocytes. (A) AWL inhibited the Akt signalling pathways in a dose-dependent manner in 3T3-L1
adipocytes. 3T3-L1 cells were differentiated with DMI in the absence or the presence of AWL for 4 or 7
days. The Akt phosphorylation was normalized to the total Akt expression level. * p < 0.05, ** p < 0.01.
(B) AWL inhibited the phosphorylation of GSK3β in 3T3-L1 adipocytes. The phosphorylation of GSK3β
was normalized to the total GSK3β expression level. The data shown are representative of at least three
independent experiments. * p < 0.05, ** p < 0.01.
3.4. AWL Reduced Body Weight Gain, Adipose Tissue Mass and Adipocyte Size in HFD-Induced Obese Rats
We examined the anti-obesity effects of AWL in HFD-induced obese rats. Body weight gain in
the HFD-fed group was higher than the body weight gain in the ND control group. In particular,
treatment with 150 mg/kg of AWL to HFD-fed rats for five weeks by oral administration significantly
reduced body weight gain (Table 1). After five weeks on the HFD, the body weights of the HFD plus
AWL group were 17% lower than that of the HFD group. Food intake was not significantly different
among all groups. These results demonstrated that AWL reduced body weight gain without affecting
food intake. To examine whether decreased body weight gain in the AWL-fed group compared to
the HFD group was associated with a decrease in fat accumulation, the weights of epididymal and
perirenal adipose tissues and the sizes of epididymal adipocytes were measured. We observed that
supplementation with 150 mg/kg of AWL markedly reduced epididymal and perirenal fat mass (40.2%
and 32.3%) compared to those of the HFD group (Figure 4A), demonstrating that the reduction in
body weight gain was primarily due to a decrease of fat accumulation in adipocytes. In obese rats, the
adipocyte sizes were validated by histological examination of the epididymal fat tissue. These results
demonstrated that the sizes of the adipocytes in the AW group were significantly reduced compared
that in the HFD group (Figure 4B).
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Table 1. Effect of AWL on body weight and food intake in rats fed HFDs for five weeks. The effect
of AWL on body weight and food intake in rats fed HFD for five weeks. Values are presented as the
mean ± S.D. (n = 10). a,b,c Means not sharing common letters are significantly different among the
groups at p < 0.05.
ND Group HFD Group HFD + AWL Group
Food intake (g/kg) 22.1 ± 0.54 21.05 ± 0.34 20.05 ± 0.44
Initial Body weight (g) 107.3 ± 3.7 107.8 ± 4.3 106.7 ± 3.8
Final body weight (g) 316.5 ± 16.8 a 411.5 ± 24.2 c 342 ± 20.5 b
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Figure 4. AWL ameliorates adiposity in HFD-induced obese rats. Rats were fed a normal diet or
high-fat diet for five weeks in the presence (150 mg/kg/day) or absence of AWL (n = 10). (A) the
weight of perirenal and epididymal fat was significantly reduced by AWL treatment. * p < 0.05;
(B) histological analysis of epididymal adipose tissue after staining with Haematoxylin and Eosin
(H&E) followed by microscopy analysis. Scale bar is 100 µm.
3.5. Effect of AWL on Serum Triglyceride and Cholesterol Content in HFD-Induced Obese Rats
Similar to the results for body weight gain and fat mass, serum TG and TC levels were significantly
higher and HDL-C was dramatically lower in the HFD group compared to the ND group. The treatment
of AWL significantly reduced the serum TG and TC levels in HFD plus AWL group compared to the
HFD alone group, while serum HDL-C levels were significantly increased in the HFD plus AWL group
compared to the HFD group (Figure 5).
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HFD alone group. HDL‐C  levels were significantly higher  in the AWL‐treated group compared to 
that  in  the HFD alone group. Statistical significance between  the HFD alone group and HFD plus 
AWL group was calculated using Duncan’s multiple range test. * p < 0.05, ** p < 0.01.   
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levels of adipogenesis‐related genes in adipocyte tissue in HFD‐treated and HFD plus AWL‐treated 
rats. Gene expression of PPARγ and C/EBPα, major  regulators  related  to  lipid  synthesis and TG 
accumulation in adipocytes, were significantly suppressed in the HFD plus AWL group compared 
to HFD alone group (Figure 6). In addition, expression of Acetyl-CoA carboxylase (ACC), which is a 
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Figure 5. Effects of AWL treatment on lipid content in HFD-induced obese rats. (A–C) significant
decreases were observed in serum TG and TC levels of the AWL-treated group compared to the HFD
alone group. HDL-C levels were significantly higher in the AWL-treated group compared to that in the
HFD alone group. Statistical significance between the HFD alone group and HFD plus AWL group
was calculated using Duncan’s multiple range test. * p < 0.05, ** p < 0.01.
3.6. Effects of A L on the mRNA Expression in hite Adipose Tissue
In order to further investigate the anti-obesity effects of A L, we compared the expression
levels of adipogenesis-related genes in adipocyte tissue in HFD-treated and HFD plus A L-treated
rats. Gene expression of PPARγ and C/EBPα, major regulators related to lipid synthesis and TG
accumulation in adipocytes, were significantly suppressed in the HFD plus A L group compared
to HFD alone group (Figure 6). In addition, expression of Acetyl-CoA carboxylase (ACC), which is a
regulator of fatty acid oxidation, was markedly increased by AWL (Figure 6). We further investigated
whether the AWL-induced reduction of PPARγ and C/EBPα regulated the expression of their target
gene, such as FAS and aP2. As expected, AWL suppressed the mRNA expression levels of aP2 and FAS
in adipose tissue of HFD–induced obese rats. Taken together, these findings indicated that AWL could
downregulate the expression of the genes involved adipogenesis and lipid metabolism in adipocytes.
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tumour  cell  lines  in  vitro  and  in  vivo  [21,22].  Additionally,  Artemisia  annua  L.  (AWL)  has 
demonstrated significant anti‐oxidant, anti‐inflammatory, and anti‐microbial properties [12]. Recent 
studies  also  reported  that  artemisinic  acid  isolated  from  Artemisia  annua  L.  (AWL)  inhibited 
adipogenic differentiation of human adipose tissue‐derived mesenchymal stem cells [16]. Although 
Figure 6. Effects of AWL on mRNA expressi i ididymal adipose tissues. AWL decreas d the
expr ssion of adipogenic factors in adipoc P Rγ, peroximal proliferator-ac ivated receptor-γ;
C/EPBα, CCAAT/enhancer bin i t in-α; A C, acetyl-CoA carboxylase; aP2, adipocyte fatty
acid-binding protein 4; FAS, fatty acid synthase. The values are presented as the means ± SD. The data
shown are representative of at least three independent experiments. β-actin expression in each sample
was used as an internal control to normalize expression. * p < 0.05.
4. Discussion
Obesity is a risk factor for multifaceted metabolic syndromes including Hyperlipidaemia, Type II
Diabetes, and Cardiovascular Disease (CVD) [1,2]. To date, considerab e amount of advancement
on target discovery using metabol mics platform with various analytical t chnologies has been
made in the field of metabolic disorder; this includes obesity. Compelling evidence supports that
natural substances and herb compounds have focused on prevention and treatment of obesity to
achieve a healthy lifestyle. Ongoing high-throughput drug screening in biomedicine leads to a major
bottleneck of synthetic chemistry strategies-driven several medications. This reflects tens of thousands
of anti-obesity compounds that have been withdrawn due to their serious side effects (biological activity
vs. toxicity). Therefore, trends of recent studies have focused on screening natural products to explore
functional core component resulting in body weight loss and reduction of levels of fat that generally
have minimal dverse effec s [18]. In similar c ntext, w have investigated the u derlying molecular
mechanism of Ar emisia annua L. (AWL), a po enti l anti-obesity effect, which could b associated with
changes in a molecular level including transcriptional factors and regulatory pathway in adipocyte
differentiation and lipogenesis using 3T3-L1 adipocytes as cellular models and HFD-induced obese
rats in animal models.
Continuous efforts to elucidate molecular network of obesity accumulated evidence that a key
feature of secondary metabolites from Artemisia annua L. (AWL) possesses a number of biological
activities [19,20]. For example, it can exhibit anti-proliferative effects or induce apoptosis in
various tumour cell lines i vitro and in vivo [21,22]. A ditio all , Artemisia annua L. (AWL) has
demonstrated significant anti-oxidant, anti-inflammatory, and anti-microbial properties [12]. Recent
studies also reported that artemisinic acid isolated from Artemisia annua L. (AWL) inhibited adipogenic
differentiation of human adipose tissue-derived mesenchymal stem cells [16]. Although numerous
studies have demonstrated that AWL has a potential role as an anti-cancer therapy, there is limited
information available about the anti-obesity effects of AWL.
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As a key biological target, adipose tissue plays an important role as a storage depot for excess
energy and regulates body energy homeostasis. Adipocyte hyperplasia and hypertrophy, as a result of
inadequate adipogenesis in fat tissues, lead to obesity. Adipocyte differentiation from preadipocyte
into mature adipocytes is a highly controlled process that involves changes in gene expression and
the enlargement of intracellular lipid droplets [23]. In the present study, we confirm inhibition of
lipid accumulation by measuring intracellular triglyceride level staining with Oil Red O in 3T3-L1
adipocytes. This could lead to a significant reduction in adipogenesis in a dose-dependent manner of
AWL without cell cytotoxicity. Furthermore, our in vivo study showed marked interventions in which
AWL strongly reduced body weight gain, adipose mass, and adipocyte hypertrophy. Therefore, our
findings suggest that AWL exerted anti-obesity effects in adipocytes and in HFD-induced obese rats.
Several transcription factors regulate adipocyte differentiation, in particular, C/EBPs and PPARγ,
which synergistically activate the expression of adipocyte-specific genes to transform preadipocyte into
mature adipocytes [24]. PPARγ is a ligand-activated transcription factor that regulates adipogenesis
during the early to terminal phase of differentiation. C/EBPα is expressed in the mid to late stages
of adipogenesis and stimulates the differentiation of preadipocytes in cooperation with PPARγ [6].
Moreover, PPARγ-deficient cells fail to differentiate into adipocytes, and overexpression of PPARγ, while
C/EBPα accelerates adipogenesis [25]. In this study, our findings unfold the molecular regulation of
obesity by which AWL effectively inhibited the expression of C/EBPβ, C/EBPα, and PPARγ at the mRNA
and protein levels. PPARγ and C/EBPα synergistically trans activate downstream adipocyte-specific
gene expression, including aP2 enhancer, which is directly associated with lipogenic pathways [26].
These results manifested the molecular link of obesity through the treatment of AWL inhibited the
expression of aP2, which facilitate AWL driven suppression of adipogenesis via the downregulation of
C/EBPα and PPARγ on molecular dysregulation in disease complications such as obesity.
Obesity causes insulin resistance, which may be associated with health complications such as
diabetes, hyperlipidemia, and hypertension. There is a clear premise that the insulin signalling
pathway plays a critical role in insulin-induced adipogenesis. Akt is an important signal mediator
in the insulin-like growth factor 1 receptor signal cascade, which is involved in the induction of
adipocyte differentiation [27]. Ectopic expression of activated Akt induces the differentiation of 3T3-L1
pre-adipocytes into adipocytes [28,29]. Moreover, the overexpression of PPARγ in Akt-deficient mouse
embryonic fibroblasts rescued their severe adipogenesis defect [30], which supports the essential role
of PPARγ induction downstream of Akt. In the present study, we found that AWL treatment induced
a dose-dependent decrease in Akt phosphorylation and subsequently reduced the phosphorylation level
of GSK3β. Both observations could be partly involved in the dysfunction of adipogenesis or lipogenesis.
Emerging results including us, AWL-induced functional inactivate, such as inhibition of PPARγ and
C/EBPα expression, might be influenced to the decreased level of Akt phosphorylation. Therefore, our
results provide the first evidence that AWL inhibited insulin-mediated Akt phosphorylation, which,
in turn, dramatically reduced adipogenic triglyceride accumulation by downregulating the PI3K/Akt
pathway during the differentiation of 3T3-L1 preadipocytes into adipocytes.
Consistent with the inhibitory effect of AWL on adipocyte lipid accumulation, an in vivo study
indicated that AWL prevented obesity in HFD-induced obese rats. The body weight of rats fed an HFD
was lowered by 17% following administration of AWL compared to the HFD alone group. The reduced
weight gain in AWL-fed rats was accompanied by a reduction in the weights of epididymal and
perirenal adipose tissues. We examined the effect of AWL on adipogenesis- and/or obesity-related
gene expression in adipose tissue of HFD-induced obese rats. The expressions of PPARγ and C/EBPα
in adipose tissue of the AWL group were downregulated; subsequently, the gene expression of aP2
and FSA were decreased by treatment with AWL. Moreover, ACC, a PPAR-regulated fatty acid
oxidation gene, was upregulated. Thus, our findings suggest that AWL significantly suppressed the
expression of PPARγ and C/EBPα genes, which may regulate adipogenesis-related gene expression,
fatty acid synthase, and lipogenesis in adipocytes. We also observed that AWL administration
resulted in the improvement of numerous serum metabolic parameters, decreasing serum TG, TC, and
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increasing HDL-C levels, which are used as an indicator of adipocyte lipolysis. In addition, histological
examination showed smaller fat cells in the epididymal fat tissue of the AWL-fed group in comparison
to that in the HFD alone group, indicating that the decreased body weight gain was due to the reduced
accumulation of fat. According to our observations, both natural and synthetic compounds from AWL
shed light on new avenues of anti-obesity progression and/or blunt underlying obesity linked insulin
resistance underlying metabolic health complications.
5. Conclusions
In summary, our data demonstrated that AWL suppressed 3T3-L1 adipogenic differentiation via
the inhibition of Akt phosphorylation and C/EBPs and PPARγ expression. Moreover, AWL attenuated
HFD-induced weight gain, fat deposition, and adipose cell size, and alleviated serum TC, TG, and
HDL-C levels. These results that were obtained from in vivo and in vitro levels suggest that AWL
could significantly enhance pathophysiological symptoms in obesity animal models and thus may be
an effective alternative therapeutic agent in preventing obesity and other related metabolic disorders.
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